Investors Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw unusually large options trading on Wednesday. Traders acquired 33,531 call options on the company. This represents an increase of approximately 180% compared to the average daily volume of 11,957 call options.

Wall Street Analyst Weigh In

Several brokerages have commented on RXRX. KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.75.

Recursion Pharmaceuticals Stock Up 8.9 %

RXRX opened at $7.49 on Thursday. The company has a market cap of $2.93 billion, a PE ratio of -4.90 and a beta of 0.85. The company has a 50-day moving average price of $6.86 and a 200 day moving average price of $6.94. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $15.74. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the company earned ($0.43) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. Sell-side analysts expect that Recursion Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the sale, the director now directly owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,894 shares of company stock worth $279,279 over the last 90 days. Company insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at about $25,000. Decker Retirement Planning Inc. acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at approximately $26,000. GAMMA Investing LLC lifted its stake in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares during the period. Finally, KBC Group NV grew its stake in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after buying an additional 3,377 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.